> ## Content Index
> Fetch the complete content index at: https://adjacent.media/llms.txt
> Use this file to discover other available public pages before exploring further.

# Why GLP-1 drugs are forcing a reckoning on obesity patents
- URL: https://adjacent.media/signals/why-glp-1-drugs-are-forcing-a-reckoning-on-obesity-patents/
- Published: 2026-10-11T10:11:16.000Z
- Updated: 2026-10-11T10:11:16.000Z
- Description: The obesity rate’s decline—driven by GLP-1 drugs like Ozempic—is creating pressure to rethink how pharmaceutical patents work when they genuinely shift public health outcomes.
- Author: Jonathan Greene
- Tags: #signal, theme-culture, policy, health regulation, pharmaceutical innovation

Source: [Fortune](https://fortune.com/2026/10/10/glp1-drugs-patents-innovation-competition/?ref=adjacent.media)

The obesity rate's decline—driven by GLP-1 drugs like Ozempic—is creating pressure to rethink how pharmaceutical patents work when they genuinely shift public health outcomes. Novo Nordisk and Eli Lilly's dominance in GLP-1s may face legal or regulatory challenges as governments and competitors question whether patent protections are justified when the drugs address a crisis affecting 100+ million Americans. The core question: does the current patent system adequately balance innovation incentives against population health needs when a single drug class becomes the primary solution to a decades-long epidemic.